trans-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 941666-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: trans-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• 英文别名: cis-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine；5-iodo-7-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrrolo[2,3-d]pyrimidin-4-amine
• CAS: 941666-77-9
• 化学式: C₁₇H₂₅IN₆
• 分子量: 440.33
• InChiKey: DEKNBIOFDZJCBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine 以 1,4-二氧六环 、 ammonium hydroxide 为溶剂， 生成 trans-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Pyrrolopyrimidines as therapeutic agents

  摘要：

  具有结构式I1的化合物及其生理上可接受的盐和代谢物是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。

  公开号：

  US20030153752A1

文献信息

• Inhibitors of protein kinases
  申请人：Michaelides R. Michael

  公开号：US20070135387A1

  公开（公告）日：2007-06-14

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  揭示了抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法。
• [EN] PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINES UTILISEES COMME INHIBITEURS DE PROTEINES KINASES
  申请人：BASF AG

  公开号：WO2000017203A1

  公开（公告）日：2000-03-30

  Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.

  具有结构式（I）和生理上可接受的盐及其代谢物的化合物是丝氨酸/苏氨酸和酪氨酸激酶活性的抑制剂。这些化合物抑制的多种激酶参与免疫、过度增殖或血管生成过程。因此，这些化合物可以改善与血管生成或内皮细胞过度增殖有关的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病、类风湿性关节炎、免疫系统紊乱、移植排斥和炎症性疾病。
• AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA
  申请人：RIKEN

  公开号：US20150210698A1

  公开（公告）日：2015-07-30

  This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar 1 and Ar 2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C 1-3 -alkylene; Z 1 represents hydrogen, C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkylamino-C 1-6 -alkyl, di(C 1-6 -alkyl)amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, or carboxy-C 1-6 -alkyl; and Z 2 represents C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkylamino-C 1-6 -alkyl, di(C 1-6 -alkyl)amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, or carboxy-C 1-6 -alkyl, Z 1 and Z 2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z 1 and Z 2 .

  本发明涉及一种用于治疗或抑制急性髓性白血病复发的药物和一种抑制白血病干细胞生长的药物，包括式（I）或其盐所表示的化合物：其中Ar1和Ar2分别表示芳基或杂环芳基；L表示O、S、NH、NHCO或CONH；X表示CH或N；Y表示C1-3-烷基；Z1表示氢、C1-6-烷基、氨基-C1-6-烷基、C1-6-烷基氨基-C1-6-烷基、二（C1-6-烷基）氨基-C1-6-烷基、羟基-C1-6-烷基、C1-6-烷氧基-C1-6-烷基或羧基-C1-6-烷基；Z2表示C1-6-烷基、氨基-C1-6-烷基、C1-6-烷基氨基-C1-6-烷基、二（C1-6-烷基）氨基-C1-6-烷基、羟基-C1-6-烷基、C1-6-烷氧基-C1-6-烷基或羧基-C1-6-烷基，Z1和Z2可以与相邻的氮一起形成含有一个或多个杂原子的杂环基团，除了与Z1和Z2相邻的氮。
• AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA
  申请人：Riken

  公开号：EP2878601B1

  公开（公告）日：2018-03-28
• PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1114053A1

  公开（公告）日：2001-07-11